← All trials
NCT00068601
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2003
- Primary completion
- Jan 1, 2014
- Completion date
- Sep 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 257
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Southwest Oncology GroupLead sponsor
- University of RochesterOverall official - principal investigator
- Loyola UniversityStudy chair
- John Wayne Cancer InstituteStudy chair
- Harvard UniversityStudy chair
- Temple UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- Eastern Cooperative Oncology GroupCollaborator
- International Breast Cancer Study GroupCollaborator
- Cancer and Leukemia Group B (CALGB)Collaborator
- Peter MacCallum Cancer CentreStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.